| Term 
 | Definition 
 
        | Anolog of Adriamycin (doxorubacin) and used in patients with cardiovascular risk |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | analog of cisplatin and has less nephrotoxic effects |  | 
        |  | 
        
        | Term 
 
        | cell cycle phase specific |  | Definition 
 
        | antimetabolites and vinka alkaloids |  | 
        |  | 
        
        | Term 
 
        | cell cycle phase non-specific |  | Definition 
 
        | alkylating agents and cisplatin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | refractory to chemotherapy |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Procarbazine, Antimetabolites, hydroxyurea, canptothecins |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | bleomycin, vinka alkaloids, taxanes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | vinka alkaloids and taxanes |  | 
        |  | 
        
        | Term 
 
        | nitrogen mustards (classic alkylating |  | Definition 
 
        | mechlorethamine, melphalan, cyclophosphamide, chlorambucil |  | 
        |  | 
        
        | Term 
 
        | nitrosoureas (classic alkylating) |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | carboplatin, cisplatin, oxaliplatin |  | 
        |  | 
        
        | Term 
 
        | non-classic alkylating agents |  | Definition 
 
        | procarbazine and bendamustine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | most favored residue for DNA alkylation leading to cross-linking |  | 
        |  | 
        
        | Term 
 
        | interstrand cross-linking |  | Definition 
 
        | guanine on 2 opposite strands |  | 
        |  | 
        
        | Term 
 
        | intrastrand cross-linking |  | Definition 
 
        | guanine on 2 different strands |  | 
        |  | 
        
        | Term 
 
        | ALL Alkylating agents: SE |  | Definition 
 
        | myelosuppression, GI toxicity and N/V |  | 
        |  | 
        
        | Term 
 
        | mechlorethamine side chain |  | Definition 
 
        | small side chain allows for most potent activity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | longer side chain with cyclic group that make it have moderate activity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | very lipophilic allowing for blood brain barrier penetration, only ones used for brain cancer |  | 
        |  | 
        
        | Term 
 
        | mechloroethamine for Hodgkin's and non-Hodgkin's lymphoma |  | Definition 
 
        | paired with vincristine, procarbazine, prednisone |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | extravasation can occur, myelosuppression, N/V, alopecia and menstrual irregularities |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | prodrug that must be activated through hydroxylation into haldol phosphamide |  | 
        |  | 
        
        | Term 
 
        | phosphoramide mustard and acrolein (toxic) |  | Definition 
 
        | active metabolites of cyclophosphamide |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | bladder irritation due to acrolein toxicity; ameliorated with SH donors and large fluid intake |  | 
        |  |